ALBUQUERQUE, N.M., Jan. 11 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, announced today Dr. Stephen M. Gomez has joined Biomoda as a Senior Research Specialist focused on the company's efforts to commercialize its assay for the early detection of lung cancer.
Dr. Gomez most recently worked as an associate research scientist at Lovelace Respiratory Research Institute in Albuquerque. He was an instructor in genetics at the University of New Mexico and consultant to national laboratories and UCLA. He is the author of nearly a dozen publications on proteomics and photosystems including his dissertation at the University of California, Los Angeles, on pigment-binding proteins.
"Dr. Gomez's experience and expertise in molecular, cell and development biology is of particular importance and use at Biomoda where we have developed a mechanism that preferentially binds to cancer cells and glows red under a microscope for easy and accurate detection of the disease," explained John Cousins, President of Biomoda. "I am pleased to have him working side-by-side with our team of exceptional scientists in the development and application of our assay by the medical community."
Dr. Gomez was awarded a Masters of Biology by the University of California before going on the get his Ph.D. in Molecular, Cell and Development Biology from the same institution. He holds a bachelors degree in biology from the California Institute of Technology, Pasadena.
Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
Contact: John Cousins
|SOURCE Biomoda, Inc.|
Copyright©2008 PR Newswire.
All rights reserved